用于放射免疫显像和治疗的抗体药物研究现状  

Current status of radioimmunoimaging and radioimmunotherapeutic antibody drugs

作　　者：曾永龙 邓启民 刘媛媛 王邦金 

机构地区：[1]成都云克药业有限责任公司,610041

出　　处：《中华核医学与分子影像杂志》2016年第2期196-200,共5页Chinese Journal of Nuclear Medicine and Molecular Imaging

摘　　要：放射性核素标记的单克隆抗体能够特异地与肿瘤相关抗原结合，以该药物为基础的RIT和RII用于肿瘤治疗和诊断，是非常有效的方法。越来越多的RIT和RII相关药物进入临床前和临床研究．笔者对目前研究现状作一综述。Radiolabeled monoclonal antibodies can specifically bind to tumor-associated antigens. On this immune basis, RIT and RII have therefore been used in the diagnosis and treatment of cancer. Many RIT and RII pharmaceuticals were applied in trials of preclinical and clinical phases, and excellent results had been achieved. This paper reviews on the current status of RIT and RII pharmaceuticals.

关 键 词：放射免疫显像 放射免疫疗法 抗体 单克隆 发展趋势 

分 类 号：R392[医药卫生—免疫学]